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AB ST RA C T   
 
With this study we evaluated the performance of a histological method for 
the detection of microscopic lesions in the sexual accessory glands of veal 
calves administered 17b-estradiol valerate for growth promotion; our goal 
was to determine whether the method might hold potential as an official 
screening technique according to the Commission Decision 2002/657/EC. 
The target organs of veal calves treated with low-dose 17b-estradiol valerate 
and those of control animals were microscopically examined in blinded 
manner and the histolopathogical features scored by two pathologists. 
Distinct histopathological differences were seen in the prostate and the 
bulbo-urethral glands of the treated animals versus the controls. Our 
findings indicate that, compared with the negative results obtained with the 
official test, this histopathological method can identify illicit 17b-estradiol 
valerate treatment up to 15 days after the last drug administration. 
Based on the preliminary evidence for the method’s high specificity and 
sensitivity, a validation study could be set up according to Decision 
2002/657/EC. Confirmation of its performance could support adoption of 
histopathology as an official screening method in the National Residue 
Monitoring Program for the detection of illicit estrogenic treatment.
 INTRODUCTION 
 
Estrogens, of which 17b-estradiol is the most active molecule, constitute a 
group of steroid compounds known for their importance in the estrous cycle. 
Conventionally called the female sex hormones, these naturally occurring 
substances are formed out of androgen precursors, such as 4-androstenedione, 
through the action of the enzyme aromatase in the ovaries, in the adipose tissue 
of the adrenal glands and in other organs (Nebbia, 2009). These steroids 
stimulate the development of the female reproductive structures and 
secondary sexual characteristics. Besides their function in the reproductive 
cycle, they also play an important role in a number of other physiological 
processes, including mineral, fat, sugar and protein metabolism, intestinal 
motility, blood coagulation, cholesterol metabolism, sodium and water 
conservation by the kidneys (Noppe, Le Bizec, Verheyden, & De Brabander, 
2008), and in all strategically important tissues to improve protein anabolism 
and mineral retention (Meyer et al., 1995; Sauerwein, Pfaffl, Hagen-Mann, 
Malucelli, & Meyer, 1995). 
Owing to their wide-reaching systemic effects, estrogens are also illegally 
administered to stimulate growth in calves and boost meat production (Guarda, 
Biolatti, & Miglietti, 1990; Meyer, 2001; Meyer, Sauerwein, & Mutayoba, 
1990; Smith, Wilson, & Swanson, 1999). Since the treatment of cattle with 
sex steroid hormones exposes humans to an increased intake of residues 
through the consumption of meat from treated animals, the use of hormonal 
drugs in animal meat production has been officially prohibited in Europe since 
1989 (The Council of the European Union (1996) Council Directive 
96/22/EC). 
Council Directive 96/23/EC requires Member States to adopt and implement a 
National Residue Monitoring Plan to control the illicit use of growth promoters 
for fattening purposes. The Directive sets forth sampling levels and frequency, 
as well as the group of substances to be monitored for each category of live 
animals or animal products (The Commission of the European Communities, 
1996, Council directive 96/23/EC). 
Although 17b-estradiol use in food producing animals has been banned since 
2008 (The European Parliament and the Council of the European Union 
(2002) European Parliament and Council Directive 2008/97/EC) due to its 
potential carcinogenicity, investigations and analysis of illegal preparations 
have shown that steroids, natural hormones and b agonists are still widely in 
use. 
Under current legislation, analytical screening and confirmatory methods 
applied in National Monitoring Plans employ chemical analysis of specific 
target compounds; however, this approach allows for fraudulent compliance 
with EC requirements as samples tested a few days after the last drug 
administration test negative because  these  molecules  are  rapidly  
metabolised  or  because available tests fail to detect new and/or unknown 
substances (Cai & Henion, 1997; Hewitt, Kearney, Currie, Young, & Kennedy, 
2002; Van Poucke & Van Peteghem, 2002). With regard to 17b-estradiol 
investigations, Italian legislation prescribes serum as the matrix to be used for 
official analysis (Ministerial Decree 14 November, 1996). To control the illegal 
use of 17b-estradiol and ensure consumer protection, sensitive analytical 
methods need to be developed. In this context,  bioassays  which  detect  
estrogens  have  proven economic, fast and robust techniques as early warning 
systems for the illicit use of hormonal treatments, and a yeast bioassay has 
recently been validated for screening purposes (Bovee et al., 2009). 
Histopathological examination of the sexual accessory glands (prostate and 
bulbo-urethral glands in the male, Bartholini’s glands in the female) is an older 
monitoring approach that, like bioactivity- based methods, is both economic 
and quick and can identify the indirect effects of estrogenic treatment on target 
organs (Groot & Biolatti, 2004; Groot et al., 2007; Groot, Schilt, 
Ossenkoppele, Berende, & Haasnoot, 1998; Kroes, Berkvens, Loendersloot, & 
Ruitenberg, 1971; Schilt et al., 1998; Weijman, Zwart, Vos, & Ramaekers, 
1996).  Despite these advantages, its reliability for screening purposes is still 
questionable due to the lack of accuracy evaluation studies. 
With this present study we evaluated the performance of a histological method 
for the detection of microscopic lesions in the sexual accessory glands of male 
veal calves experimentally treated with 17b-estradiol valerate to promote 
growth. Our goal was to determine whether the method might hold potential as 
an official screening technique according to Commission Decision 2002/657/ 
EC (The Commission of the European Communities (2002). Commission 
Decision 2002/657/EC). 
 
MATERIALS AND METHODS 
 
ANIMALS AND EXPERIMENTAL DESIGN 
 
In all, 108 male veal calves aged between 15 and 35 days were bought from local 
breeders, divided into two homogenous groups based on body weight and age, 
and housed in two pens under controlled conditions for 6 months according to 
Council Directive 86/609/EEC. Each pen had its own crib, multiple drinking 
troughs, and a dedicated automated milk feeder system. To protect the animals 
against infection, all were vaccinated against IBR, Para influenza (PI3), BRSV 
and BVDV (CATTLEMASTER 4 Pfizer Animal Health, New York, USA). 
Clinical evaluation was carried out daily by a veterinarian and comprised a 
daily observation and, if necessary, a physical assessment. Treatments for 
occurring infections were performed without using hormonal active substances. 
The animals had free access to fresh water and were fed standard milk replacer 
with an automatic milk feeder until 4 months of age, then 0.5 kg of corn was 
added to the diet twice a day. Before administration, all feeds, milk replacer 
and corn were analyzed with an ELISA test to exclude the presence of hormonal 
active substances. During the sixth month of the study period, 17b-estradiol 
valerate was administered by intramuscular injection in the neck at a dose of 5 
mg once a week for four weeks to 69 randomly selected animals; placebo was 
administered to the remaining 39 animals used as controls. The trial was 
conducted in a blinded manner. Fifteen days after the last injection, all animals, 
aged between 6.5 and 7 months, were slaughtered 10 a day in a CE-certified 
slaughterhouse. 
All experiments were carried out according to European Economic 
Community Council Directive 86/609, recognised and adopted by the Italian 
Government (D.L. 27/01/1992 no. 116). 
 
CHEMICAL ANALYSIS BY LIQUID CHROMATOGRAPHY E TANDEM MASS 
SPECTROMETRY (LCEMS/MS) 
 
SAMPLE COLLECTION 
 
Blood samples of 10 treated animals and 10 controls were collected before 
the first administration, and at 6 and 12 h after each treatment, at 24 and 48 h 
after the last treatment, and at the slaughterhouse. The serum was obtained 
from each sample and stored at   80°C until use. 
 
CHEMICALS AND REAGENTS 
 
17a-Estradiol, 17b-estradiol, estriol, estrone, formestane (internal standard 
[IS]), acetonitrile, methanol, tert-butylmethylether, acetone, Dansyl chloride 
and formic acid (Sigma-Aldrich, St. Louis, MO, USA), sodium hydrogen 
carbonate were supplied from Merck (Darmstadt, Germany); blank reference 
serum was obtained from non-treated animals and tested to verify the absence 
of the analytes. 
Stock standard solutions of 17a-estradiol, 17b-estradiol, estriol and estrone were 
prepared in methanol at a concentration of 1000 mg/L and stored at 20°C in the 
dark. 
Calibration curves at five concentration levels (0, 20, 50, 100 and 500 ng/L for 
each analyte) were obtained by spiking blank serum with 17a-estradiol, 17b-
estradiol, estriol and estrone working solutions. 
 
SAMPLE PREPARATION 
 
3 mL of serum sample were transferred into a 25 mL glass tube and 30 mL of   
the internal standard solution   (formestane 10 ng/mL) were added. The sample 
was subjected to liquid/liquid extraction by adding 10 mL of diethylether. The 
centrifuge tube was shaken vigorously for 5 min with a vortex multimixer 
(Tecnovetro, Monza, Italy) and then centrifuged at 3500 rpm for 5 min (Mega- 
fuge 1.0 Heraeus, ASHI, Milan, Italy). The supernatant organic phase was 
transferred into a 10 mL glass tube and evaporated to dryness under  a  gentle  
stream  of  nitrogen  and  heating  (50°C)  using a Techne Sample Concentrator 
(Barloworld Scientific, Stone, UK). The residue was redissolved in 50 mL of 
hydrogen carbonate buffer 0.1 M (pH 10.5), and 50 mL of Dansyl chloride 
solution (1 mg/mL in acetone) were added. The sample was shaken for a few 
seconds, transferred into the heater block and kept at 60°C for 6 min. The 
derivatized extract was then transferred into the analytical vials for the 
LCeMS/MS analysis. 
 
 
Analyte CCa, (ng L 
1) CCb (ng L  
1) 
17a-Estradiol, 26 32 
17b-Estradiol, 28 36 
Estriol 28 35 
Estrone 29 37 
 
INSTRUMENTATION 
 
Chromatographic separations were performed on an Agilent 1100 series liquid 
chromatograph (Agilent Technologies, Palo Alto, CA, USA) equipped with a 
Merck LiChroCART - C18 (5 mm) 150 4.6 mm column and a Phenomenex 
SecurityGuard 4. 2 mm pre-column (Phenomenex, Torrance, CA, USA). The 
chromatographic run was carried out with a binary mobile phase of acetonitrile (A) 
and 0.05% formic acid in water (B) using the following isocratic conditions: 85% 
Ae15% B. Total run time was 19 min, the injection volume was 20 mL, and the flow-
rate was 0.5 mL/min. The LC was interfaced to an Applied Biosystems API 4000 
triple-quadrupole mass spectrometer (Applied Biosystems Sciex, Ontario, Canada) 
operating in atmospheric pressure chemical ionization (APCI) e positive ion mode. 
The other MS parameters were set as follows: curtain gas 15 psi; nebulizer gas 30 
psi; probe temperature 350 C; gas for collisional activation N2 at 2 psi; nebulizer 
current 3 mA; entrance potential 10 V. 
Ion acquisition was operated at unit mass resolution in the multiple reaction 
monitoring (MRM) mode using the transitions from the protonated molecular 
ion of each analyte to the fragment ion indicated in Table 1. 
 
Table 1. API4000 mass spectrometer acquisition parameters: ion 
source and collision cell potentials, product ion acquired for each 
analite. 
 
 
VALIDATION AND METHOD PERFORMANCE 
 
Specificity, precision (in terms of repeatability and within- laboratory 
reproducibility), trueness, CCa, CCb and ruggedness were estimated according to 
Commission Decision 2002/657/EC, from data collected at 3 different 
concentration levels (20, 40 and 60 ng/L for each analyte). Validation results 
match the 2002/657/ EC prescriptions, CCa, CCb values are reported in Table 2. 
 
Table 2. Decision limit (CCa) and decision capability (CCb) for 17b-
estradiol and its methabolites, evaluated accordingly to the 
commission decision 2002/657/EC. 
 
 
 
Analyte Ion precursor m/z Declustering 
potential (V) 
Product ions m/z Collision energy (V) Collision cell exit 
potential (V) 
17a-Estradiol 506.3 60 506.3 / 170.3 50 10 
   506.3 / 171.2 60  
17b-Estradiol 506.3 60 506.3 / 170.3 50 10 
   506.3 / 171.2 60  
Estriol 522.3 50 522.3 / 170.3 45 10 
   522.3 / 171.3 60  
Estrone 504.3 50 504.3 / 170.3 50 10 
   504.3 / 171.2 50  
Formestane 
(IS) 
536.2 70 536.2 / 170.3 50 10 
   536.2 / 171.1 50  
HISTOPATHOLOGIC  ANALYSIS 
 
Tissue samples of the prostate and sexual accessory glands of each animal 
were fixed in formalin, trimmed, routinely processed, embedded in paraffin wax, 
sectioned at 3 2 mm and stained with haematoxylin and eosin (HE). 
Histopathologic examination was blindly performed by two veterinarians. The 
slides were examined for estrogenic effects such as changes in urethra 
(hyperplasia, metaplasia) and in the glandular tissue (hyperplasia, metaplasia, 
cistys) in prostate or in ducts (hyperplasia, metaplasia) and glandular tissue 
(hyperplasia, metaplasia, cistys) in bulbo-urethral glands. Lesions were semi- 
quantitatively scored on a scale from 0 to 3 (absent, mild, moderate, severe). 
 
 
IMMUNOHISTOCHEMISTRY 
 
Immunohistochemical analysis was performed with mono- clonal antibodies 
CK5 (RCK 103 clone, Novocastra heat-induced epitope retrieval pH 6, 1:100) 
and CK7 (OV-TL 12/30 clone, Dako enzyme retrieval pk, 1:100) to 
characterize the cells involved in metaplastic change. 
Prostate and sexual accessory glands of both treated and control animals were 
sectioned at 3.2 mm, mounted on electrostatic slides and put at 37°C for at 
least 12 h. Then they were deparaffinized with atoxic substitute of xylene and 
hydrated through a series of decreasing concentrated ethanol solutions and 
rinsed successively in distilled water. 
After hydration slides were incubated with 0.3% ethanol hydrogen peroxide 
for 30 min at room temperature to inhibit endogenous peroxidase activity and 
to overcome the effect of fixation heat-induced epitope retrieval pH 6 was 
performed for monoclonal antibodies CK5, while  enzyme  retrieval  with  pk 
for CK7. 
The EnVision System Kit (Dako) for polyclonal and monoclonal antibodies was 
used as immunohistochemical detection system. Positively stained cells 
showed a golden dark brown 3.3-diaminobenzidine tetrahydrocloridee H2O2 
reaction product. At the end, after counterstained with haematoxylin, slides 
were dehydrated through series of increasing concentrated ethanol solutions, 
put in atoxic substitute of xylene and mounted for examination. 
In control sections the primary antibody was replaced by PBS. 
 
 
STATISTICAL ANALYSIS 
 
The results of the microscopic examination were entered into an ad hoc database, 
cleaned and analyzed using Stata 10.1 SE (Stata- Corp, College Station, TX, 
USA). In order to test for statistically significant differences between the treated  
animals  and  the controls, and as the data were not normally distributed, we 
per- formed a test of hypothesis for non-parametric data using the Wilcoxon 
rank-sum test (Mann-Whitney). The validity of the evaluation of the 
histopathological lesions was evaluated for those parameters that resulted 
significantly associated with the treatment. 
 
 
RESULTS AND DISCUSSION 
 
CHEMICAL ANALYSIS 
 
Results of chemical analysis are shown in Table 3. Analysis of serum collected 
at 12 h after the last treatment showed the presence of 17b-estradiol in all 10 
samples (concentration range, 57e224 ng/L; average, 132 ng/L); 9/10 samples 
tested positive for 17b-estradiol (concentration  range,  30-132 ng/L,  average: 60 
ng/L) at 24 h after the last treatment and 9/10 samples tested positive 
(concentration range, 28-137 ng/L, average 45 ng/L) at 48 h after the last 
treatment. Respectively three and four out of 10 samples resulted negative after 
the second and the third treatment both at 6 and 12 h. Furthermore no 17b-
estradiol residues were detected by LCeMS/MS analysis on serum samples 
collected before the second and the third 17b-estradiol administration, except 
for one animal; finally all samples taken at the slaughterhouse gave negative 
results.  17a-estradiol metabolites were detected (57 ng/L) in one sample taken 
at 48 h after the last treatment. Neither estriol nor estrone were detected in any 
of the samples. 
 
Table 3. Results of chemical analysis. 
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The Italian legislation provides (Ministerial Decree 14 November 1996) a 17b-
estradiol serum concentration threshold value of 40 ng/L in order to 
discriminate between endogenous and exogenous origin of the estrogen. The 
LCeMS/MS method described in the present work and used for the chemical 
analysis gives a Decision limit or CCa (minimum concentration at and above 
which the analyte can be detected and quantified with known accuracy and 
precision) sharply below the legislation limit (see Table 2) our data show that 
official sampling performed on serum in the farm, would have little chance to 
detect the illicit treatment with low-dosage 17b-estradiol, and no chance at 
slaughterhouse. 
 
 
 
 
 
Fig. 1. TREATED ANIMAL-effect of 17b-estradiol on glandular tissue of 
the bulbo-urethral gland. A: Severe metaplasia of the glandular tissue of the 
bulbo-urethral gland (HE 10X); B: Strong immunopositivity of metaplastic 
basal cells (CK5 10X); C: Mild metaplasia of the glandular tissue of the 
bulbo-urethral gland (HE 10X); D: Mild immunopositivity of metaplastic 
basal cells (CK 5 10X). 
 
 
  
Fig. 2. CONTROL ANIMAL e bulbo-urethral gland. A: Normal glandular 
tissue of the bulbo-urethral gland with cubic epithelia (HE 4X); B: Normal 
staining pattern of basal cells (CK5 4X). 
 
 
HISTOPATHOLOGY  ANALYSIS 
 
Normal histology of the disseminated prostate gland is characterised by alveoli 
lined with a low epithelium constituted of cylindrical and cubical cells, while 
the urethra is covered with a transition epithelium. Bulbo-urethral glands are 
an agglomerate of glandular lobules made up of mucinuos, acinous tubulo-
alveolar glands with a central excretory duct. The epithelium covering the 
glandular tissue in male veal calves is cubic or simple prismatic while the 
ducts are covered with a simple bathyprismatic epithelium. 
The most striking feature of the lesions in the treated animals was the 
dramatic metaplasia of the glandular tissue of the prostate and of the ducts and 
glandular tissue of the bulbo-urethral glands. Metaplasia in the glandular 
tissue of the prostate was observed in 51/69 treated animals as compared to 
normal epithelium in all the control animals; mild-to-severe duct metaplasia 
in the bulbo-urethral glands was noted in 67/69 treated animals and in the 
glandular tissue of 66/69 animals versus mild metaplasia seen in only one 
control animal. Histological patterns observed in the controls aided in 
clarifying which microscopic findings can be related to physiological 
conditions of veal cattle, thus narrowing the spectrum of lesion features related 
to illicit drug treatment. To date, pathologists have described all organ lesions 
but without identifying the most significant. With this new approach, 
histological results can be standardized, which would permit simplification of 
microscopic interpretation and limit the margin of subjectivity implicit in the 
histological method. Furthermore, accuracy evaluation, as a fundamental 
parameter for the application of the technique as an official screening method, 
could be performed. 
 
 
 
IMMUNOHISTOCHEMISTRY 
 
In the prostate and sexual accessory glands of the treated and the control 
animals, the basal cell layer was immunoreactive with monoclonal antibody 
CK5 (RCK 103 clone, Novocastra, Newcastle upon Tyne, UK) and the 
urothelial cells were immunoreactive with monoclonal antibody CK7 (OV-TL 
12/30 clone, Dako, Glostrup, Denmark). 
Immunohistochemical analysis highlighted basal cell (CK5þ; CK7) 
involvement in the metaplastic change but no involvement of the urothelial 
cells (CK7þ; CK5) (Figs. 1 and 2). The detection of metaplastic changes in 
the epithelial cells appeared to be facilitated by immunohistochemistry with 
cytokeratin antibodies, as previously described for prostate analysis 
(Weijman et al., 1996). 
 
 
STATISTICAL ANALYSIS 
 
Statistical differences in the microscopic patterns of the treated and the control 
animals emerged on the Wilcoxon rank-sum test. Table 4 reports lesion 
characteristics and their sensibility and specificity. 
Glandular metaplasia of the bulbo-urethral gland was found to be the most 
sensitive and specific parameter (Se 95.7%, 95% CI 87.8-99.1); (Sp 97.4%, 95% 
CI 86.5-99.9). 
 
 
Table 4. The diagnostic performances of each single histopathological 
feature are expressed in terms of Sensitivity and Specificity. The 
difference between treated and control group is measured by a non-
parametric test (Wilcoxon rank-sum test). 
 
 Wilcoxon rank-sum test 
(ManneWhitney) 
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% 
   Sp 
97.40% 86.50% 99.90
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Iperplasia, secretion and cysts were not significantly associated with the 
treatment. 
CONCLUSIONS 
 
The object of this study was to investigate how estrogen could influence target 
organs histology and which microscopical parameters are a reliable marker of 
treatment. 
Until now only one European country, The Netherlands, performed 
histological screening to reveal estrogenic illicit treatment in veal calves giving 
positive on squamous metaplasia of prostate. Nevertheless, a large amount of 
other microscopical parameters, such as thickened urethra, dysplasia of the 
epithelium; dilated tubules, hyperplasia secretion and vacuolisation in glands, 
have been considered to be related to the treatment (Schilt et al., 1998). Our 
findings show that by identifying a single histological feature (metaplasia of 
the bulbo-urethral glands) the illicit use of 17b-estradiol can be exposed even 
after 2 weeks of suspension of low-dosage treatment. This method has a high 
sensitivity value compared with the official chemical methods, which, when 
applied to serum samples collected at slaughterhouse detected neither the 
molecule nor its metabolites. The histological method could provide a rapid and 
inexpensive tool of valuable interest to overcome current limitations in the 
control of growth promoters’ abuse and it could be used to detect illicit 
treatment with a potentially carcinogenetic molecule at the slaughterhouse.  
Accuracy data suggest widening the experiment to obtain the sample size 
needed for validation in order to comply with the Commission Decision 
2002/657/EC requirements for biological screening. Following the validation it 
could be considered as a new promising approach in term of screening to 
evidence the diffusion of estrogen illicit treatment  in  farm  animals  in  
order  to  orientate  controls  by confirmatory methods. 
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